Back to Search Start Over

PDXNet portal: patient-derived Xenograft model, data, workflow and tool discovery.

Authors :
Koc S
Lloyd MW
Grover JW
Xiao N
Seepo S
Subramanian SL
Ray M
Frech C
DiGiovanna J
Webster P
Neuhauser S
Srivastava A
Woo XY
Sanderson BJ
White B
Lott P
Dobrolecki LE
Dowst H
Evrard YA
Wallace TA
Moscow JA
Doroshow JH
Mitsiades N
Kaochar S
Pan CX
Chen MS
Carvajal-Carmona L
Welm AL
Welm BE
Lewis MT
Govindan R
Ding L
Li S
Herlyn M
Davies MA
Roth J
Meric-Bernstam F
Robinson PN
Bult CJ
Davis-Dusenbery B
Dean DA 2nd
Chuang JH
Source :
NAR cancer [NAR Cancer] 2022 Apr 22; Vol. 4 (2), pp. zcac014. Date of Electronic Publication: 2022 Apr 22 (Print Publication: 2022).
Publication Year :
2022

Abstract

We created the PDX Network (PDXNet) portal (https://portal.pdxnetwork.org/) to centralize access to the National Cancer Institute-funded PDXNet consortium resources, to facilitate collaboration among researchers and to make these data easily available for research. The portal includes sections for resources, analysis results, metrics for PDXNet activities, data processing protocols and training materials for processing PDX data. Currently, the portal contains PDXNet model information and data resources from 334 new models across 33 cancer types. Tissue samples of these models were deposited in the NCI's Patient-Derived Model Repository (PDMR) for public access. These models have 2134 associated sequencing files from 873 samples across 308 patients, which are hosted on the Cancer Genomics Cloud powered by Seven Bridges and the NCI Cancer Data Service for long-term storage and access with dbGaP permissions. The portal includes results from freely available, robust, validated and standardized analysis workflows on PDXNet sequencing files and PDMR data (3857 samples from 629 patients across 85 disease types). The PDXNet portal is continuously updated with new data and is of significant utility to the cancer research community as it provides a centralized location for PDXNet resources, which support multi-agent treatment studies, determination of sensitivity and resistance mechanisms, and preclinical trials.<br /> (© The Author(s) 2022. Published by Oxford University Press on behalf of NAR Cancer.)

Details

Language :
English
ISSN :
2632-8674
Volume :
4
Issue :
2
Database :
MEDLINE
Journal :
NAR cancer
Publication Type :
Academic Journal
Accession number :
35475145
Full Text :
https://doi.org/10.1093/narcan/zcac014